In precision cancer therapy,addressing intra-tumor heterogeneity poses a significant obstacle.Due to the heterogeneity of each cell subtype and between cells within the tumor,the sensitivity and resistance of differen...In precision cancer therapy,addressing intra-tumor heterogeneity poses a significant obstacle.Due to the heterogeneity of each cell subtype and between cells within the tumor,the sensitivity and resistance of different patients to targeted drugs,chemotherapy,etc.,are inconsistent.Concerning a specific tumor type,many feasible treatments or combinations can be used by specifically targeting the tumor microenvironment.To solve this problem,it is necessary to further study the tumor microenvironment.Single-cell sequencing techniques can dissect distinct tumor cell populations by isolating cells and using statistical computational methods.This technology may assist in the selection of targeted combination therapy,and the obtained cell subset information is crucial for the rational application of targeted therapy.In this review,we summarized the research and application advances of single-cell sequencing technology in the tumor microenvironment,including the most commonly used single-cell genomic and transcriptomic sequencing,and their future development direction was proposed.The application of single-cell sequencing technology has been expanded to include epigenomics,proteomics,metabolomics,and microbiome analysis.The integration of these different omics approaches has significantly advanced the development of single-cell multiomics sequencing technology.This innovative approach holds immense potential for various fields,such as biological research and medical investigations.Finally,we discussed the advantages and disadvantages of using single-cell sequencing to explore the tumor microenvironment.展开更多
Primary liver cancer,which is mainly composed of hepatocellular carcinoma(HcC),is the sixth most common type of cancer worldwide and the thirdmost common cause of cancer mortality.1 The total number of mutations prese...Primary liver cancer,which is mainly composed of hepatocellular carcinoma(HcC),is the sixth most common type of cancer worldwide and the thirdmost common cause of cancer mortality.1 The total number of mutations present in tumor specimens is called tumor mutation burden(TMB)and it is an emerging biomarker of immunotherapy response.2 TMB can predict clinical responses to immunotherapy such as ICl(immune checkpoint inhibitor)treatments and higher TMB is related to better survival.3 TP53,a gene encoding a tumor suppressor protein that triggers apoptosis and cell cycle arrest,is one of the most prevalent mutations in 25%-30%of HCC patients.4 Research shows that TP53 mutations in HCC patients are associated with advanced tumor grade and poor prognosis.5 To identify the TP53 mutation-related genes which can predict HCC patients'prognosis and explore the immune cell infiltration,we constructed a risk model based on six TP53 mutation-related genes which can accurately predict patients'prognosis.Besides,six immune cells with a similar expression pattern were identified in The Cancer Genome Atlas(TCGA)and International Cancer Genome Consortium(ICGC)databases.展开更多
Pancreatic cancer is one of the most lethal malignant tumors in the world.Despite advances in diagnosis and treatment,the five-year survival rate for pancreatic cancer patients remains only 9%.1 Pancreatic adenocarcin...Pancreatic cancer is one of the most lethal malignant tumors in the world.Despite advances in diagnosis and treatment,the five-year survival rate for pancreatic cancer patients remains only 9%.1 Pancreatic adenocarcinoma(PAAD)belongs to pancreatic cancer,which occupies 85%of the whole pancreatic cancer.2 Reversible modification of Ne-methyladenosine(m^(6)A)has been shown to be involved in cancer progression,resulting in up-regulation of oncogene expression or down-regulation of tumor-suppressing genes and may affect the prognosis of patients with pancreatic cancer.展开更多
文摘In precision cancer therapy,addressing intra-tumor heterogeneity poses a significant obstacle.Due to the heterogeneity of each cell subtype and between cells within the tumor,the sensitivity and resistance of different patients to targeted drugs,chemotherapy,etc.,are inconsistent.Concerning a specific tumor type,many feasible treatments or combinations can be used by specifically targeting the tumor microenvironment.To solve this problem,it is necessary to further study the tumor microenvironment.Single-cell sequencing techniques can dissect distinct tumor cell populations by isolating cells and using statistical computational methods.This technology may assist in the selection of targeted combination therapy,and the obtained cell subset information is crucial for the rational application of targeted therapy.In this review,we summarized the research and application advances of single-cell sequencing technology in the tumor microenvironment,including the most commonly used single-cell genomic and transcriptomic sequencing,and their future development direction was proposed.The application of single-cell sequencing technology has been expanded to include epigenomics,proteomics,metabolomics,and microbiome analysis.The integration of these different omics approaches has significantly advanced the development of single-cell multiomics sequencing technology.This innovative approach holds immense potential for various fields,such as biological research and medical investigations.Finally,we discussed the advantages and disadvantages of using single-cell sequencing to explore the tumor microenvironment.
文摘Primary liver cancer,which is mainly composed of hepatocellular carcinoma(HcC),is the sixth most common type of cancer worldwide and the thirdmost common cause of cancer mortality.1 The total number of mutations present in tumor specimens is called tumor mutation burden(TMB)and it is an emerging biomarker of immunotherapy response.2 TMB can predict clinical responses to immunotherapy such as ICl(immune checkpoint inhibitor)treatments and higher TMB is related to better survival.3 TP53,a gene encoding a tumor suppressor protein that triggers apoptosis and cell cycle arrest,is one of the most prevalent mutations in 25%-30%of HCC patients.4 Research shows that TP53 mutations in HCC patients are associated with advanced tumor grade and poor prognosis.5 To identify the TP53 mutation-related genes which can predict HCC patients'prognosis and explore the immune cell infiltration,we constructed a risk model based on six TP53 mutation-related genes which can accurately predict patients'prognosis.Besides,six immune cells with a similar expression pattern were identified in The Cancer Genome Atlas(TCGA)and International Cancer Genome Consortium(ICGC)databases.
基金approved by the Medical Research Ethics Committee of the First Affiliated Hospital of Nanchang University[reference number:(2023)CDYFYYLK(05-023)].
文摘Pancreatic cancer is one of the most lethal malignant tumors in the world.Despite advances in diagnosis and treatment,the five-year survival rate for pancreatic cancer patients remains only 9%.1 Pancreatic adenocarcinoma(PAAD)belongs to pancreatic cancer,which occupies 85%of the whole pancreatic cancer.2 Reversible modification of Ne-methyladenosine(m^(6)A)has been shown to be involved in cancer progression,resulting in up-regulation of oncogene expression or down-regulation of tumor-suppressing genes and may affect the prognosis of patients with pancreatic cancer.
